Targeting a specific protein to improve treatment for a type of leukemia
Official title: Mechanism and therapeutic opportunities of targeting the Tudor domain
Funded at Beckman Research Institute/city of Hope · NIH-10992652 · Data updated 2026-11-12
This study is looking at a protein called SGF29 to see how it affects a tough type of leukemia, with the hope of finding new ways to improve treatment and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $460,155 |
| NIH project number | 5R01CA278050-03 |
| Project ID | NIH-10992652 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with MLL-rearranged acute leukemia.
✕Less likely to help
Patients with other types of leukemia or those without MLL-rearrangements may not benefit from this research.
What this research studies
This research investigates the role of a protein called SGF29 in MLL-rearranged leukemias, which are a challenging form of acute leukemia with poor outcomes. The study aims to understand how SGF29 interacts with other proteins to influence cancer cell behavior and gene expression. By using advanced techniques like CRISPR, researchers will explore the potential of targeting SGF29 alone or in combination with existing treatments to enhance therapeutic effectiveness. The goal is to develop new treatment strategies that could lead to better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with MLL-rearranged leukemia.
How similar studies have gone: Other research has shown promising results in targeting epigenetic mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Chen, Chun-Wei David — Beckman Research Institute/city of Hope
- Study coordinator: Chen, Chun-Wei David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.